VEGF: Necessary to prevent motoneuron degeneration, sufficient to treat ALS?

Trends in Molecular Medicine

Volumn 10, Issue 6, 2004, Pages 275-282

  Lambrechts, Diether ^a   Storkebaum, Erik ^a   Carmeliet, Peter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; RILUZOLE; VASCULOTROPIN;

ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; HUMAN; MOTONEURON; MOUSE MUTANT; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STROKE; VASCULARIZATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, KNOCKOUT; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 2642585619     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.04.004     Document Type: Review

References (66)

1. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62
2. Gurney M.E., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 264:1994;1772-1775
3. Reaume A.G., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13:1996;43-47
4. Brown R.H. Jr, Robberecht W. Amyotrophic lateral sclerosis: pathogenesis. Semin. Neurol. 21:2001;131-139
5. Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2:2001;806-819
6. Julien J.P. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell. 104:2001;581-591
7. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344:2001;1688-1700
8. Majoor-Krakauer D., et al. Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet. 63:2003;83-101
9. Sapp P.C., et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am. J. Hum. Genet. 73:2003;397-403
10. Ruddy D.M., et al. Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am. J. Hum. Genet. 73:2003;390-396
11. Robberecht W. Genetics of amyotrophic lateral sclerosis. J. Neurol. 247:2000;2-6
12. Lacomblez L., et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet. 347:1996;1425-1431
13. Ferrara N., et al. The biology of VEGF and its receptors. Nat. Med. 9:2003;669-676
14. Carmeliet P., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439
15. Ferrara N., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442
16. Carmeliet P., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:2001;575-583
17. Carmeliet P., Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann. N. Y. Acad. Sci. 902:2000;249-262
18. Breier G., et al. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 114:1992;521-532
19. Dumont D.J., et al. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev. Dyn. 203:1995;80-92
20. Millauer B., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835-846
21. Mukouyama Y.S., et al. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell. 109:2002;693-705
22. Haigh J.J., et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev. Biol. 262:2003;225-241
23. Bagnard D., et al. Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor. J. Neurosci. 21:2001;3332-3341
24. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat. Rev. Genet. 4:2003;710-720
25. Forsythe J.A., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:1996;4604-4613
26. Carmeliet P., Conway E.M. Growing better blood vessels. Nat. Biotechnol. 19:2001;1019-1020
27. Oosthuyse B., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28:2001;131-138
28. Stalmans I., et al. VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat. Med. 9:2003;173-182
29. Lambrechts D., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34:2003;383-394
30. Brogan I.J., et al. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol. 60:1999;1245-1249
31. Stein I., et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol. Cell. Biol. 18:1998;3112-3119
32. Miller D.L., et al. The vascular endothelial growth factor mRNA contains an internal ribosome entry site. FEBS Lett. 434:1998;417-420
33. Huez I., et al. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol. Cell. Biol. 18:1998;6178-6190
34. van der Velden A.W., Thomas A.A. The role of the 5′ untranslated region of an mRNA in translation regulation during development. Int. J. Biochem. Cell Biol. 31:1999;87-106
35. Huez I., et al. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol. Endocrinol. 15:2001;2197-2210
36. Meiron M., et al. New isoforms of VEGF are translated from alternative initiation CUG codons located in its 5′UTR. Biochem. Biophys. Res. Commun. 282:2001;1053-1060
37. Lang-Lazdunski L., et al. Spinal cord ischemia. Development of a model in the mouse. Stroke. 31:2000;208-213
38. Carmeliet P., Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 13:2002;39-53
39. Waldemar G., et al. Focal reductions of cerebral blood flow in amyotrophic lateral sclerosis: a [99mTc]-d, l-HMPAO SPECT study. J. Neurol. Sci. 107:1992;19-28
40. Kobari M., et al. Local cerebral blood flow in motor neuron disease: correlation with clinical findings. J. Neurol. Sci. 144:1996;64-69
41. Greenberg D.A., Jin K. VEGF and ALS: the luckiest growth factor? Trends Mol. Med. 10:2004;1-3
42. Sondell M., et al. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19:1999;5731-5740
43. Jin K., et al. Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor. Neuroscience. 108:2001;351-358
44. Rosenstein J.M., et al. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J. Neurosci. 23:2003;11036-11044
45. Thoenen H., Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 5:(Suppl):2002;1046-1050
46. Sopher B.L., et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron. 41:2004;687-699
47. Zhang Z.G., et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest. 106:2000;829-838
48. van Bruggen N., et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104:1999;1613-1620
49. Sun Y., et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 111:2003;1843-1851
50. Harrigan M.R., et al. Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume. Acta Neurochir. (Wien). 145:2003;49-53
51. Bao W.L., et al. Intraventricular vascular endothelial growth factor antibody increases infarct volume following transient cerebral ischemia. Zhongguo Yao Li Xue Bao. 20:1999;313-318
52. Benton R.L., Whittemore S.R. VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem. Res. 28:2003;1693-1703
53. Widenfalk J., et al. Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience. 120:2003;951-960
54. Miller R.G., et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39:1996;256-260
55. Kaspar B.K., et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 301:2003;839-842
56. Wang L., et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. 9:2002;381-389
57. Azzouz M., et al. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum. Mol. Genet. 9:2000;803-811
58. Lu Y.Y., et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neurosci. Res. 45:2003;33-40
59. Monahan P.E., Samulski R.J. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol. Med. Today. 6:2000;433-440
60. Xu R., et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 8:2001;1323-1332
61. Bartlett J.S., et al. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 9:1998;1181-1186
62. Schratzberger P., et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med. 6:2000;405-413
63. Palmer T.D., et al. Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol. 425:2000;479-494
64. Louissaint A. Jr, et al. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron. 34:2002;945-960
65. Machein M.R., Plate K.H. VEGF in brain tumors. J. Neurooncol. 50:2000;109-120
66. Wright A.F., et al. Population choice in mapping genes for complex diseases. Nat. Genet. 23:1999;397-404